- Home
- APLS vs NWE Comparison
APLS vs NWE Comparison
Compare APLS & NWE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLS
- NWE
- Stock Information
- Founded
- APLS 2009
- NWE 1923
- Country
- APLS United States
- NWE United States
- Employees
- APLS N/A
- NWE N/A
- Industry
- APLS Biotechnology: Pharmaceutical Preparations
- NWE Power Generation
- Sector
- APLS Health Care
- NWE Utilities
- Exchange
- APLS Nasdaq
- NWE Nasdaq
- Market Cap
- APLS 3.3B
- NWE N/A
- IPO Year
- APLS 2017
- NWE N/A
- Fundamental
- Price
- APLS $24.27
- NWE $56.80
- Analyst Decision
- APLS Buy
- NWE Buy
- Analyst Count
- APLS 18
- NWE 6
- Target Price
- APLS $45.53
- NWE $59.25
- AVG Volume (30 Days)
- APLS 1.7M
- NWE 639.4K
- Earning Date
- APLS 05-06-2025
- NWE 04-24-2025
- Dividend Yield
- APLS N/A
- NWE 4.65%
- EPS Growth
- APLS N/A
- NWE 13.41
- EPS
- APLS N/A
- NWE 3.65
- Revenue
- APLS $781,367,000.00
- NWE $1,513,898,000.00
- Revenue This Year
- APLS $12.95
- NWE $5.69
- Revenue Next Year
- APLS $21.35
- NWE $4.38
- P/E Ratio
- APLS N/A
- NWE $15.56
- Revenue Growth
- APLS 97.02
- NWE 6.45
- 52 Week Low
- APLS $23.25
- NWE $47.48
- 52 Week High
- APLS $59.91
- NWE $57.49
- Technical
- Relative Strength Index (RSI)
- APLS 40.15
- NWE 59.05
- Support Level
- APLS $23.25
- NWE $54.08
- Resistance Level
- APLS $24.88
- NWE $56.56
- Average True Range (ATR)
- APLS 0.91
- NWE 1.00
- MACD
- APLS 0.11
- NWE -0.04
- Stochastic Oscillator
- APLS 38.35
- NWE 93.15
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.